Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,762 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study.
Cortes J, Di Cosimo S, Climent MA, Cortés-Funes H, Lluch A, Gascón P, Mayordomo JI, Gil M, Benavides M, Cirera L, Ojeda B, Rodríguez CA, Trigo JM, Vazquez J, Regueiro P, Dorado JF, Baselga J; Spanish Breast Cancer Cooperative Group SOLTI. Cortes J, et al. Among authors: cortes funes h. Clin Cancer Res. 2009 Jan 1;15(1):307-14. doi: 10.1158/1078-0432.CCR-08-1113. Clin Cancer Res. 2009. PMID: 19118059 Clinical Trial.
Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts.
Morancho B, Zacarías-Fluck M, Esgueva A, Bernadó-Morales C, Di Cosimo S, Prat A, Cortés J, Arribas J, Rubio IT. Morancho B, et al. Among authors: cortes j. Oncotarget. 2016 Oct 18;7(42):67956-67965. doi: 10.18632/oncotarget.11815. Oncotarget. 2016. PMID: 27602583 Free PMC article.
Agreement between results of meta-analyses from case reports and clinical studies, regarding efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II (MPS-II). A new tool for evidence-based medicine in rare diseases.
Sampayo-Cordero M, Miguel-Huguet B, Pardo-Mateos A, Malfettone A, Pérez-García J, Llombart-Cussac A, Cortés J, Moltó-Abad M, Muñoz-Delgado C, Pérez-Quintana M, Pérez-López J. Sampayo-Cordero M, et al. Among authors: cortes j. Orphanet J Rare Dis. 2019 Oct 21;14(1):230. doi: 10.1186/s13023-019-1202-6. Orphanet J Rare Dis. 2019. PMID: 31639024 Free PMC article.
NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer.
Jacobs SA, Robidoux A, Abraham J, Pérez-Garcia JM, La Verde N, Orcutt JM, Cazzaniga ME, Piette F, Antolín S, Aguirre E, Cortes J, Llombart-Cussac A, Di Cosimo S, Kim RS, Feng H, Lipchik C, Lucas PC, Srinivasan A, Wang Y, Song N, Gavin PG, Balousek AD, Paik S, Allegra CJ, Wolmark N, Pogue-Geile KL. Jacobs SA, et al. Among authors: cortes j. Breast Cancer Res. 2019 Dec 3;21(1):133. doi: 10.1186/s13058-019-1196-y. Breast Cancer Res. 2019. PMID: 31796073 Free PMC article.
Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer.
Jacobs SA, Robidoux A, Abraham J, Pérez-Garcia JM, La Verde N, Orcutt JM, Cazzaniga ME, Piette F, Antolín S, Aguirre E, Cortes J, Llombart-Cussac A, Di Cosimo S, Kim RS, Feng H, Lipchik C, Lucas PC, Srinivasan A, Wang Y, Song N, Gavin PG, Balousek AD, Paik S, Allegra CJ, Wolmark N, Pogue-Geile KL. Jacobs SA, et al. Among authors: cortes j. Breast Cancer Res. 2020 Jan 22;22(1):9. doi: 10.1186/s13058-019-1240-y. Breast Cancer Res. 2020. PMID: 31969184 Free PMC article.
ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer.
de Azambuja E, Trapani D, Loibl S, Delaloge S, Senkus E, Criscitiello C, Poortman P, Gnant M, Di Cosimo S, Cortes J, Cardoso F, Paluch-Shimon S, Curigliano G. de Azambuja E, et al. Among authors: cortes j. ESMO Open. 2020 May;5(Suppl 3):e000793. doi: 10.1136/esmoopen-2020-000793. ESMO Open. 2020. PMID: 32439716 Free PMC article. Review.
2,762 results